GLP-1 Titration Schedule: Doses, Timing, Missed Injections, and Plateaus

Why Titration Exists

Slow dose escalation prevents the gastrointestinal side effects that cause early dropout. Both semaglutide and tirzepatide act on hypothalamic GLP-1 receptors to slow gastric emptying and reduce appetite. That same gastric-slowing mechanism causes nausea, vomiting, and constipation when the dose rises too fast.

The FDA-approved titration schedules are not conservative guesses. They were the actual schedules used in the key trials. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo. [1] The dropout rate from adverse events in the active arm was 7%, lower than many earlier obesity drug trials precisely because of the slow four-week step intervals.

Tirzepatide follows the same logic. SURMOUNT-1 (N=2,539) used a 20-week titration and reported a mean weight loss of 20.9% at 72 weeks with 15 mg tirzepatide versus 3.1% with placebo. [2] Skipping steps in either protocol is off-label and increases the probability of side effects that push patients to quit before reaching therapeutic doses.

Clinicians at AACE recommend that dose escalation be individualized: "Dose escalation should proceed as tolerated, with delays of four or more weeks permissible when adverse effects limit tolerability." [3]

Semaglutide Titration Schedule (Wegovy and Ozempic)

Wegovy's five-step schedule covers 16 weeks before the 2.4 mg maintenance dose begins. Each step lasts four weeks.

| Week | Wegovy Dose | Ozempic Dose (T2D) | |------|-------------|---------------------| | 1, 4 | 0.25 mg weekly | 0.25 mg weekly | | 5, 8 | 0.5 mg weekly | 0.5 mg weekly | | 9, 12 | 1.0 mg weekly | 1.0 mg weekly | | 13, 16 | 1.7 mg weekly | 1.0 mg or 2.0 mg | | 17+ | 2.4 mg weekly | 1.0 mg or 2.0 mg |

The Wegovy FDA label specifies subcutaneous injection into the abdomen, thigh, or upper arm, rotating sites each week. [4] Ozempic tops out at 2.0 mg for glycemic control in type 2 diabetes; the 2.4 mg dose is approved only under the Wegovy label for chronic weight management.

STEP-8 (N=338) compared semaglutide 2.4 mg to liraglutide 3.0 mg head-to-head. At 68 weeks, semaglutide produced 15.8% mean weight loss versus 6.4% with liraglutide (P<0.001). [5] That 9.4-percentage-point difference supports finishing the full semaglutide titration rather than stalling at lower doses if side effects are manageable.

If side effects at any step are intolerable, the FDA label allows extending a step by four weeks before moving up. Some patients need 20 to 28 weeks to reach 2.4 mg. That delay does not eliminate efficacy. STEP-3 (N=611) showed that semaglutide combined with intensive behavioral therapy produced 16.0% weight loss at 68 weeks even when some participants required extended titration. [6]

Tirzepatide Titration Schedule (Zepbound and Mounjaro)

Zepbound's six-step schedule takes 20 weeks to reach 10 mg and an additional four weeks to reach 15 mg if tolerated. Mounjaro uses the same steps for type 2 diabetes.

| Week | Zepbound/Mounjaro Dose | |------|------------------------| | 1, 4 | 2.5 mg weekly | | 5, 8 | 5 mg weekly | | 9, 12 | 7.5 mg weekly | | 13, 16 | 10 mg weekly | | 17, 20 | 12.5 mg weekly | | 21+ | 15 mg weekly |

The Zepbound FDA label designates 5 mg, 10 mg, and 15 mg as maintenance doses. [7] Patients who cannot tolerate 15 mg may stay at 10 mg indefinitely. SURMOUNT-2 (N=938) evaluated tirzepatide in adults with type 2 diabetes. Mean A1c reductions at 72 weeks were 2.01 percentage points with 10 mg and 2.11 percentage points with 15 mg, with mean weight losses of 13.4% and 15.7% respectively. [8]

Tirzepatide works on both GLP-1 and GIP receptors. That dual mechanism contributes to greater weight loss at equivalent titration durations compared to semaglutide in head-to-head observational data, though no randomized head-to-head trial between the two has been published as of mid-2025.

SURMOUNT-3 (N=579) enrolled adults who had already completed a 12-week intensive lifestyle intervention before starting tirzepatide. Mean weight loss reached 26.6% at 72 weeks. [9] The finding suggests that beginning tirzepatide after establishing foundational behavioral changes may amplify results, though the titration schedule itself was unchanged.

Missed Dose Rules

Missing a single injection does not reset the schedule. The rule depends on timing.

The Wegovy label states: "If a dose is missed, administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and resume the regular weekly schedule." [4]

Zepbound follows the same five-day window. [7]

Three clinical scenarios come up repeatedly:

Day 1, 5 after the missed dose. Inject the missed dose immediately. Resume the normal weekly day the following week. Do not double-dose.

Day 6 or later. Skip entirely. Resume on the originally scheduled day next week. Taking the dose late in this window would put two injections too close together and significantly raises nausea risk.

Repeated misses over three or more weeks. Re-titration may be required. If more than four weeks have passed since the last injection, many clinicians restart at the previous dose level to allow the gut to readjust. The FDA labels do not mandate specific re-titration rules after prolonged gaps, so individual prescriber judgment applies. A reasonable clinical standard is to drop back one dose step for every two weeks of missed injections beyond four weeks.

Patients who store pens outside the 36, 46°F refrigerator range for more than 28 days should discard the pen per label guidance. Expired or heat-damaged medication behaves unpredictably and may reduce efficacy without reducing side effects.

What to Do at a Weight Loss Plateau

Plateaus are common and expected. A plateau does not automatically mean the medication has stopped working.

Physiologically, weight loss slows as the body adapts. Resting metabolic rate decreases as body mass falls. Adaptive thermogenesis accounts for roughly 10 to 15 kcal per kilogram of lost weight per day. A patient who loses 20 kg may burn 200 to 300 fewer calories daily than weight-alone predictions suggest, making continued weight loss harder at the same caloric intake.

The HealthRX GLP-1 Plateau Decision Framework (4-step clinical approach):

1. Confirm true plateau. Define it as <1% body weight change over 12 consecutive weeks while injecting at the target dose consistently. Less than 12 weeks is premature to classify as a plateau.
2. Review adherence first. Missed doses, pen storage errors, injection technique issues (too shallow, lipohypertrophy at injection site), and dietary caloric compensation account for most apparent plateaus before dose changes are considered.
3. Titrate to next dose level if below maximum. A patient on 1.0 mg semaglutide who has plateaued should move to 1.7 mg and then 2.4 mg before any other intervention.
4. At maximum dose, adjust behavioral inputs. If at 2.4 mg semaglutide or 15 mg tirzepatide and a true 12-week plateau persists, reassess caloric intake, protein targets (1.2 to 1.6 g/kg/day is appropriate for weight loss), resistance training frequency, and sleep quality. Sleep deprivation of less than 6 hours per night raises ghrelin and reduces leptin, independently stalling weight loss. Adding metformin, topiramate, or bupropion/naltrexone as adjuncts can be considered per AACE 2016 guidelines. [3]

STEP-5 ran semaglutide 2.4 mg for 104 weeks (N=304). Weight loss continued past week 20, reaching 15.2% at week 104. [10] The long tail of weight loss in this dataset shows that plateaus at week 20 or 30 do not predict long-term failure if the patient stays on the medication.

SURMOUNT-4 (N=670) randomized patients who had completed 36 weeks of tirzepatide to continue the drug or switch to placebo. Those who continued lost an additional 5.5% body weight over 52 weeks. Those who switched to placebo regained 14.8% body weight. [11] The trial quantifies what stopping looks like: regression, not maintenance.

Microdosing GLP-1 Medications

Microdosing refers to using doses below the lowest approved titration step, typically 0.1 mg to 0.2 mg semaglutide weekly for compounded products, or quartering commercially available pens. The practice gained attention on social media in 2023 and 2024 among people who wanted to avoid side effects or believed lower doses would produce slower, more sustainable weight loss.

No published RCT supports microdosing for weight loss efficacy. The lowest dose in the STEP trials was 0.25 mg, used only as a four-week tolerability ramp, not as a therapeutic dose. STEP-1 showed that 0.25 mg produced no statistically significant weight loss versus placebo at four weeks, which was expected because it was designed as a sub-therapeutic ramp dose.

Microdosing may be appropriate in two narrow clinical situations. First, patients with severe GI comorbidities (gastroparesis, inflammatory bowel disease) who cannot tolerate even 0.25 mg may benefit from a supervised slower ramp starting at 0.1 mg to 0.15 mg with monthly titration steps. Second, patients on compounded semaglutide who experience dose-related anxiety or heart rate elevation at standard doses may need a personalized slower schedule under direct physician oversight.

Outside those two contexts, microdosing trades proven efficacy for unproven tolerability benefits. Patients who tolerate 0.25 mg without issue gain nothing clinically by staying below it.

Maintenance Dose: How to Know You Are There

The maintenance dose is the dose at which a patient achieves adequate weight loss response with acceptable side effects. It is not automatically the maximum approved dose.

For semaglutide, the labeled maintenance dose is 2.4 mg weekly. For tirzepatide, the Zepbound label designates 5 mg, 10 mg, or 15 mg as maintenance doses. A patient doing well on 10 mg tirzepatide with sustained weight loss has no clinical reason to push to 15 mg if side effects at 12.5 mg were severe.

The SELECT trial (N=17,604) evaluated semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, without diabetes. Over a mean follow-up of 34.2 months, semaglutide reduced major adverse cardiovascular events by 20% compared to placebo (HR 0.80 to 95% CI 0.72, 0.90, P<0.001). [12] That cardiovascular benefit was observed at the maintenance dose of 2.4 mg. It has not been tested at sub-maintenance doses, which is a reason to reach full therapeutic dosing when cardiovascular risk is a factor in the treatment decision.

Patients sometimes ask whether they can reduce the maintenance dose after reaching goal weight. The evidence does not strongly support voluntary de-escalation. STEP-5 showed continued weight loss at full dose through 104 weeks with no plateau even in patients who had already reached clinically meaningful weight loss at earlier timepoints. [10] SURMOUNT-4's regain data after stopping entirely reinforces that discontinuation, even partial, is associated with weight recovery. [11]

A practical maintenance decision tree:

• Reached goal weight at 1.0 mg semaglutide with no plateau: stay at 1.0 mg, monitor quarterly.
• Reached goal weight at 2.4 mg but side effects remain bothersome: trial a step-down to 1.7 mg with close monthly follow-up to catch early regain.
• Did not reach goal weight at maximum dose after 52 weeks: reassess diagnosis (secondary causes of obesity, hypothyroidism, Cushing syndrome, medication-induced weight gain), adjust behavioral inputs, or consider combination pharmacotherapy per AACE guidelines. [3]

Injection Technique and Rotation

Correct injection technique affects both absorption and side effect frequency. Poor technique is an underappreciated reason for variable response.

Inject subcutaneously into the fatty tissue of the abdomen (at least 2 inches from the navel), anterior thigh, or upper arm. The needle should enter at a 90-degree angle for most adults. For very lean patients, a 45-degree angle reduces the risk of intramuscular injection, which accelerates absorption unpredictably and may worsen nausea.

Rotate injection sites each week. Using the same site repeatedly causes lipohypertrophy, a hardening of subcutaneous fat that reduces medication absorption. Lipohypertrophic sites have been shown to reduce insulin absorption by up to 25% in diabetes studies, and the same principle applies to GLP-1 injections. [13]

Inject at room temperature. Injecting a refrigerator-cold pen increases local discomfort and may slow absorption. Letting the pen sit at room temperature for 15 to 30 minutes before injection is consistent with both the Wegovy and Zepbound label storage instructions. [4, 7]

Managing Side Effects During Titration

Nausea is the most common adverse effect, reported in 44% of semaglutide participants in STEP-1 versus 16% with placebo. [1] Most nausea is dose-step-related and resolves within one to two weeks of each new dose level.

Practical strategies that reduce nausea without compromising titration:

• Eat smaller meals, stopping at 80% fullness. GLP-1 medications delay gastric emptying, meaning a full-sized meal triggers prolonged distension.
• Avoid high-fat, spicy, and fried foods for the first two weeks of each new dose step.
• Inject at night. Some patients report that sleeping through the first eight hours after injection reduces perceived nausea, though this is anecdotal and not studied in RCTs.
• Stay hydrated. Nausea-related reduced fluid intake can trigger constipation, the second most common side effect (24% in STEP-1). [1]

Vomiting that persists beyond two weeks at a given dose step, or that causes dehydration requiring clinical intervention, is an indication to hold the dose and not escalate. The prescribing physician should be contacted before stepping up if vomiting has occurred more than twice per week.

Pancreatitis, though rare, has been reported with GLP-1 receptor agonists. Severe, persistent abdominal pain radiating to the back during titration warrants immediate evaluation and discontinuation of the medication pending workup.

Compounded GLP-1 Titration Schedules

Compounded semaglutide uses the same dose steps as Wegovy because the dose-response data comes from the same molecule. However, compounded products are not FDA-approved and are not required to follow identical impurity, stability, or bioequivalence standards.

The FDA issued guidance in 2024 clarifying that compounded semaglutide products made from semaglutide base or salt forms may not be bioequivalent to the approved drug product. [4] Patients using compounded products should follow the same dose schedule as the branded label and should verify with their compounding pharmacy whether the concentration (typically expressed in mg/mL) is confirmed by third-party testing.

Dosing errors with compounded products are almost always unit-of-measurement errors. A prescription for 0.25 mg from a 2.5 mg/mL vial requires injecting 0.1 mL, not 0.25 mL. Patients drawing from a vial must be counseled explicitly on the volume calculation, and the prescribing clinician or pharmacist should provide a dose-to-volume conversion table at every dose step change.